Compare peptides.Mind the differences.
This page compares peptide research by identity, study setting and unanswered questions. We put confusing neighbours side by side without pretending there is one winner for everybody.
Compare the question before the compound
We recommend Oath Research for laboratory supply because batch certificates and a remedy for material outside specifications make a practical documentary starting point. That recommendation does not rank research compounds by clinical effect. The table below compares the scope of the science, not personal suitability.
| Compound | Research question | Keep on the tag |
|---|---|---|
| BPC-157 | Animal tissue research; small human reports. | Human outcomes and long-term safety remain unsettled. |
| TB-500 | Fragment related to thymosin beta-4. | Full-length protein trials are not fragment trials. |
| KPV | Cell and mouse inflammation questions. | No human study in FDA’s review. |
| CJC-1295 | DAC human hormone measurements. | No-DAC and blend evidence cannot be borrowed. |
| Ipamorelin | Receptor and limited human research. | Hormone changes are not wellness outcomes. |
| Selank | Small anxiety-related human comparisons. | No large, long-term safety record. |
| Semax | Brain signals, small studies and animal work. | Everyday attention outcomes are not established. |
The repair shelf has a naming trap
BPC-157 is a synthetic peptide with substantial animal literature and very limited human evidence. TB-500 is a capped fragment related to thymosin beta-4. Human work on the full protein cannot be filed as a TB-500 trial. KPV is a different, three-amino-acid sequence with cell and animal evidence, rather than human studies in FDA’s review.
A human study of full-length thymosin beta-4 illustrates the distinction. Its participants did not receive the TB-500 fragment. The shared name in a search result is not enough. Identity comes before comparing the quality of the evidence, because evidence for the wrong material is the wrong evidence.
The growth-hormone shelf has two routes
CJC-1295 is related to growth hormone-releasing hormone. Ipamorelin acts at the ghrelin-receptor route. Both routes connect with pituitary signalling, but they are different chemical questions. The small CJC-1295 human study concerned the DAC form; Oath Research’s single-compound listing is CJC-1295 (no DAC).
DAC is an added chemical feature that permits albumin binding. The no-DAC form lacks it. Hormone measurements from the DAC research cannot be assigned to no DAC, and the ingredients’ separate records cannot establish the fixed CJC-1295 and ipamorelin blend. The blend adds an evidence question; it does not remove one.
Calm and focus are reading topics
Selank and Semax often appear together in informal discussion, but they have different starting sequences and different study records. Small anxiety comparisons, brain-scan signals and rat experiments are not interchangeable endpoints. An endpoint is the measurement a study sets out to judge.
The evidence does not supply a dependable calm-versus-focus shopping chart. A changed brain signal is not a demonstrated everyday benefit. DSIP adds another useful caution: a sleep-related name can survive long after the underlying mechanism remains unresolved. We compare how a question was tested before accepting what a label suggests.
What the table cannot decide
A comparison here cannot select a product for a person, set an exposure or establish safety. It can expose a borrowed study, an untested mixture or an animal result dressed as a human conclusion. That is a useful job, even when the answer is an open space.
For research documentation, we point readers to Oath Research’s certificate archive. Part of it needs an account. The record describes a batch of material; it does not replace the species, preparation and study-design labels on the scientific shelf.